Fig 1.
Measurement of recombinant FSH using stable cell lines co-expressing FSHR and cAMP biosensor.
Recombinant FSH (GONAL-f) was quantified using stable cell lines co-expressing the human FSH receptor (FSHR) and GloSensor cAMP biosensor. FSH stimulation induced a concentration-dependent increase in luminescence, indicating activation of the cAMP signaling pathway.
Table 1.
Intra-assay and inter-assay variations of the FSH bioassay.
Fig 2.
Dilution linearity in the FSH bioassay.
The samples were serially diluted with FSH-depleted human serum to assess the dilution linearity of the assay. All three specimens demonstrated good linearity in FSH bioactive concentrations.
Table 2.
Effects of coexisting substances on FSH bioactive concentrations measurement.
Fig 3.
Correlation between serum FSH immunoreactive concentrations and FSH bioactive concentrations.
The relationship between serum FSH immunoreactive concentrations and FSH bioactive concentrations was evaluated in 30 postmenopausal women. A strong positive correlation was observed with a slope of 1.107 and a correlation coefficient of r = 0.955.
Table 3.
Comparison of age, serum FSH immunoreactive concentrations, FSH bioactive concentrations, FSH ratio, and E2 levels before and after E2 replacement therapy.
Fig 4.
Correlation between serum FSH immunoreactive concentrations and FSH bioactive concentrations before and after E2 replacement therapy in postmenopausal women.
In postmenopausal women, the correlation between serum FSH immunoreactive concentrations and bioactive concentrations was analyzed before (A) and after (B) E2 replacement therapy. The slope of the regression line was 1.034 before and 1.283 after therapy, indicating a shift in their relationship after treatment.